Locomotive Syndrome Stage 1 Predicts Significant Worsening of Future Motor Performance: The Prospective Yakumo Study.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
05
2019
revised:
03
09
2019
accepted:
13
09
2019
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
27
3
2020
Statut:
epublish
Résumé
Aging of society has increased the need for prolongation of a healthy lifespan through maintenance of physical function. Prediction of future physical function may be possible by screening for stage 1 locomotive syndrome (LS). In this prospective study, we examined the influence of LS stage 1 at baseline (2011) on physical performance after 5 years (2016) in a community-dwelling cohort. The participants were elderly adults aged >40 years who attended public health checkups as part of the Yakumo Study. LS screening in 2011 and 2016 was performed using the 25-question geriatric locomotive function scale (GLFS-25), the stand-up test, and the two-step test. LS of stage 1 or 2 was defined if the participant met the criteria in any of the three tests. Participants not meeting LS criteria were defined as the no risk group. Physical performance tests (10 m gait time, back muscle strength, 3 m TUG, and maximum stride) were also performed in 2011 and 2016. A total of 113 subjects (49 males, 64 females; average age 65.0 years) were followed from 2011 to 2016. At baseline, 73 (65%) had no risk, 29 (25%) had stage 1 LS, and 11 (10%) had stage 2 LS. Five years later, 51 (45%) had no risk, 45 (40%) had stage 1 LS, and 17 (15%) had stage 2 LS. Of the 73 subjects with no risk at baseline, 23 (32%) had stage 1 LS and 1 (1%) had stage 2 LS after 5 years. The baseline stage 1 LS group had significantly worse physical performance after 5 years, compared to the baseline no risk group ( This longitudinal study showed that stage 1 LS screening is important for prevention of motor dysfunction in middle-aged and elderly people.
Identifiants
pubmed: 31687379
doi: 10.1155/2019/1970645
pmc: PMC6794969
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1970645Informations de copyright
Copyright © 2019 Kazuyoshi Kobayashi et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Arch Osteoporos. 2011;6:13-20
pubmed: 22207875
J Orthop Sci. 2012 Nov;17(6):782-8
pubmed: 22961424
Eur Spine J. 2014 Jul;23(7):1414-9
pubmed: 24578093
J Bone Miner Metab. 2001;19(6):331-7
pubmed: 11685647
Mod Rheumatol. 2018 Mar;28(2):334-338
pubmed: 28612640
J Orthop Sci. 2014 Jul;19(4):612-9
pubmed: 24668310
J Orthop Sci. 2013 Jul;18(4):618-26
pubmed: 23543267
J Orthop Sci. 2008 Jan;13(1):1-2
pubmed: 18274847
J Orthop Sci. 2012 Mar;17(2):163-72
pubmed: 22222445
Clin Rev Bone Miner Metab. 2016;14:119-130
pubmed: 27375372
Mod Rheumatol. 2013 Sep;23(5):939-44
pubmed: 22996232
J Orthop Sci. 2019 Jul;24(4):720-724
pubmed: 30630769
Eur Spine J. 2012 Nov;21(11):2149-57
pubmed: 22370926
Mod Rheumatol. 2018 Nov 24;:1-17
pubmed: 30474461
J Am Geriatr Soc. 2010 May;58(5):844-52
pubmed: 20406319
Mod Rheumatol. 2019 Jun 13;:1-5
pubmed: 31132288
J Bone Miner Metab. 2015 Mar;33(2):186-91
pubmed: 24770998
J Orthop Sci. 2009 Jan;14(1):1-2
pubmed: 19214680
J Orthop Sci. 2016 Mar;21(2):216-21
pubmed: 26806334
Nagoya J Med Sci. 2013 Feb;75(1-2):47-55
pubmed: 23544268
Mod Rheumatol. 2019 May;29(3):491-495
pubmed: 29652197
Mod Rheumatol. 2017 Nov;27(6):1051-1056
pubmed: 28933238
Arch Osteoporos. 2018 Apr 05;13(1):39
pubmed: 29623499
Clin Rev Bone Miner Metab. 2016;14:56-67
pubmed: 27375370
J Orthop Sci. 2012 Sep;17(5):532-7
pubmed: 22791242
J Orthop Sci. 2015 Sep;20(5):906
pubmed: 26305292
J Orthop Sci. 2011 Sep;16(5):489-91
pubmed: 21789538